Literature DB >> 15912961

CD200 and its receptors as targets for immunoregulation.

Reginald M Gorczynski1.   

Abstract

A diverse array of cell surface receptors is known to control immune function, reflecting the integration of positive and negative signaling. Many receptors with opposing functions are isoforms of molecules with similar extracellular domains and different intracellular signaling cytoplasmic domains. The receptor(s) for the relatively ubiquitously expressed cell-surface molecule CD200 (previously referred to as OX2), CD200R(s) is one example of such paired receptors, a feature confirmed by structural and functional analysis. Expression of CD200Rs is most apparent in tissues of myeloid/macrophage origin, although some expression on lymphoid cells has also been documented. This review discusses new data in the field, and the evidence that agonists/antagonists of CD200 or the different CD200Rs might contribute to the treatment of numerous diseases, including allergy, autoimmunity, transplantation and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15912961

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  36 in total

1.  Global expression profiling of peripheral Qa-1-restricted CD8αα+TCRαβ+ regulatory T cells reveals innate-like features: implications for immune-regulatory repertoire.

Authors:  Shaohsuan S Fanchiang; Radu Cojocaru; Mohammad Othman; Ritu Khanna; Matthew J Brooks; Trevor Smith; Xiaolei Tang; Igor Maricic; Anand Swaroop; Vipin Kumar
Journal:  Hum Immunol       Date:  2011-08-17       Impact factor: 2.850

2.  Immunization with Mycobacterium vaccae induces an anti-inflammatory milieu in the CNS: Attenuation of stress-induced microglial priming, alarmins and anxiety-like behavior.

Authors:  Matthew G Frank; Laura K Fonken; Samuel D Dolzani; Jessica L Annis; Philip H Siebler; Dominic Schmidt; Linda R Watkins; Steven F Maier; Christopher A Lowry
Journal:  Brain Behav Immun       Date:  2018-05-26       Impact factor: 7.217

3.  Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.

Authors:  Zhengming Xiong; Elisabet Ampudia-Mesias; Rob Shaver; Craig M Horbinski; Christopher L Moertel; Michael R Olin
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

4.  CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response.

Authors:  E Simelyte; S Alzabin; I Boudakov; R Williams
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 5.  Microglia: Neuroimmune-sensors of stress.

Authors:  Matthew G Frank; Laura K Fonken; Linda R Watkins; Steven F Maier
Journal:  Semin Cell Dev Biol       Date:  2019-01-09       Impact factor: 7.727

6.  Recent advances in understanding the mechanisms of osteoclast precursor fusion.

Authors:  Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

7.  Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction.

Authors:  Young-June Kim; Su-Jung Park; Hal E Broxmeyer
Journal:  J Immunol       Date:  2011-07-27       Impact factor: 5.422

8.  Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?

Authors:  Douglas G Walker; Lih-Fen Lue
Journal:  Future Neurol       Date:  2013-05

Review 9.  Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Authors:  Karène Mahtouk; Dirk Hose; John De Vos; Jérôme Moreaux; Michel Jourdan; Jean François Rossi; Thierry Rème; Harmut Goldschmidt; Bernard Klein
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

10.  Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.

Authors:  Brian T Kawasaki; Tashan Mistree; Elaine M Hurt; Madhuri Kalathur; William L Farrar
Journal:  Biochem Biophys Res Commun       Date:  2007-10-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.